Furthermore, we can rescue the defects pharmacologically by HDAC6 inhibition and by genetic silencing of HDAC6, which suggests that this could become a new therapeutic strategy for ALS. The gene discussed is HDAC6; the disease is amyotrophic lateral sclerosis.